ALSO NOTED: Canada drafting bulk drug rules; Topamax approved for new indication; Schering-Plough wins FDA OK; Neurochem NDA un

> As expected, Canadian health officials say they have begun to draft new regulations that would stop bulk drug shipments going south. But the move is unlikely to threaten the online pharmacies currently in operation. Article

> The FDA has approved Johnson & Johnson's Topamax as an initial monotherapy for epilepsy. Release

> The FDA has approved Schering-Plough's Avelox for certain skin infections. Release

> The FDA has agreed to review Neurochem's NDA for Fibrillex, an investigational product candidate for the treatment of Amyloid A (AA) Amyloidosis. Release

> The FDA has accepted two BLAs from Merck for two of its investigational vaccines: Rotateq and Zostavax. Release

> The first Vioxx trial is set to start in less than two weeks in Texas. Story

> The FDA has sent Endo Pharmaceuticals a warning letter over its Lidoderm direct mail pieces. Release

And Finally... Canada's MDS has agreed to refund up to 2 million claims for work that was either covered or already paid by insurers. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.